Microencapsulated saccharomyces and its application

Abstract

A yeast in the form of micro capsule for controlling the release of protein medicine to treating uremia, hepatal failure, phenylketonuria, cancer etc has the sodium alginate-polylysine-chitosan structure. The yeast is dispersed in the liquid contained in the microcapsule.

Description

technical field [0001] The invention relates to a microencapsulated yeast that can grow, metabolize and secrete genetically engineered medicine in the intestinal tract. [0002] The present invention also relates to the application of the above-mentioned microencapsulated yeast in treating diseases. Background technique [0003] Genetic engineering drugs make it possible to cure many diseases such as tumors, immunodeficiency diseases, and genetic defect diseases [Document 1: Pennisi E. Breakthrough of the year. Genomics comes of age. Science, 2000, 290 (5500): 2220-2221], [Document 2: Peltonen L, McKusick VA. McKusick. Genomics and medicine. Dissecting human disease in the postgenomic era. Science, 2001, 291(5507): 1224-1229]. However, there are still some problems in the use of genetic engineering drugs at present, such as the extraction of genetic engineering drugs from the metabolites of genetically engineered bacteria (Escherichia coli or yeast), the separation and puri...

AI Technical Summary

Problems solved by technology

[0006] First, in the selection of strains, Escherichia coli as the host bacteria of intestinal cell microreactors limits the scope of application of microreactors

Because: ① Escherichia coli is a prokaryotic cell, most of the expressed protein products are gathered in the cytoplasm in the form of inclusion bodies and cannot be secreted outside the cell; ② The protein products expressed in E. coli cannot be modified after transcription, and often have no biological activity; ③Escherichia coli, as the host cell of genetically engineered bacteria, cannot express long gene fragments; ④Escherichia coli, as an oral dosage form, is difficult to be accepted by patients due to the odor;

[0007] Second, as the carrier material of the microreactor - polylysine, it is expensive ($345 / g)

[0008] Third, using chitosan alone as a film-forming material to prepare ACA microcapsules reduces the production cost, but the mechanical strength is not as good as that of APA microcapsules prepared using polylysine

[0009] In addition to the reports in the above literature, there is no report on the adhesion properties of polylysine to the small intestine.

Images